Nkarta, Inc.

NASDAQ:NKTX

Biotechnology

Healthcare
$1.15 +3.41%

+$0.09 today

Market cap
$82.37M
Beta
0.90
P/E (TTM)
-2.0
EPS (TTM)
-$1.35
52W Low $1.63High $3.65

Volume 0.81M

Average 0.75M

NKTX Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

Nkarta, Inc.NASDAQ: NKTX

Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Financing cash flow outflow grows to $6K

Q1 FY2026 financing cash flow was $6K, compared with $0 a year earlier. Trailing-twelve-month financing cash flow was $147K. Over 3 fiscal years it compounded at -91.4% a year.

Context

  • Financing cash flow increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly financing cash flow holds near $6K or moves back toward the trailing-twelve-month quarterly average of $36.75K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$6K-90.6% QoQ
Last fiscal yearDec 2025
$141K-99.9% YoY
LTMMar 2026
$147K+180.8% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-99.9%——
3-year CAGR-91.4%——
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
141K USD
Year-over-year change
-99.9%
4-year CAGR
-41.5%

Financing Cash Flow vs competitors

How NKTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +180.8% is the 3rd highest of 8, against a peer median of +44.8%.
  • Over three fiscal years its annual growth of -91.4% compares with a peer median of +20.1%.
NKTX Competitors
Financing Cash Flow for NKTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VORVor Biopharma Inc.LTM Mar 2026$579.28M USD+999.4%+62.6%—
PEPGPepGen Inc.LTM Mar 2026$109.5M USD+6044.6%-1.3%—
FBRXForte Biosciences, Inc.LTM Mar 2026$71.76M USD+44.8%+112.4%—
ELTXElicio Therapeutics, Inc.LTM Mar 2026$34.39M USD-17.4%+20.1%—
ALECAlector, Inc.LTM Mar 2026$20.24M USD+94.0%+64.8%109.9%
FATEFate Therapeutics, Inc.LTM Mar 2026$5.49M USD+24.7%-15.8%86.9%
MOLNMolecular Partners AGLTM Mar 2026CHF 1.3M CHF-109.0%-9.9%—
NKTXNkarta, Inc.LTM Mar 2026$147K USD+180.8%-91.4%—
Peer median (excluding NKTX) —+44.8%+20.1%98.4%

Competitors are the stored peer set for NKTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(86.08M)(113.84M)(117.5M)(108.79M)(104.08M)
Depreciation & Amortization1.76M2.64M5.87M2.24M4.61M
Deferred Income Tax3.24M0000
Stock-Based Compensation14.46M16.86M17.2M16.73M8.56M
Change in Working Capital(1.64M)33.74M10.93M(12.16M)(435K)
Accounts Receivables00000
Inventory00000
Accounts Payables2.79M2.76M4.22M(4.47M)2.46M
Other Working Capital(4.44M)30.98M6.7M(7.69M)(2.9M)
Other Non-Cash Items337K3.61M(2.65M)2.29M2.65M
Operating Cash Flow(67.93M)(57M)(86.16M)(99.7M)(88.7M)
Capital Expenditures(5.03M)(47.11M)(28.15M)(4.41M)(1.21M)
Acquisitions (Net)(37.56K)137.58K000
Purchases of Investments(227.28M)(385.89M)(260.23M)(406.38M)(238.57M)
Sales of Investments264.84M248.31M367.4M281.23M340.09M
Other Investing Activities37.56K(137.58K)000
Investing Cash Flow32.53M(184.69M)79.02M(129.56M)100.32M
Debt Repayment00000
Common Stock Issued1.2M217.17M691K225.07M141K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities01.84M01.01M0
Financing Cash Flow1.2M219.01M691K226.08M141K
Effect of Forex Changes00000
Net Change in Cash(34.19M)(22.68M)(6.45M)(3.17M)11.76M
Free Cash Flow(72.95M)(104.11M)(114.31M)(104.11M)(89.91M)

Nkarta, Inc.

NASDAQ:NKTX

Intrinsic Alpha fair value

Locked

Current Price

$1.15

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.